Every 8-K that Imax Corp (IMAX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMAX filings page.
IMAX CORP (IMAX) amended the employment agreement of Chief Legal Officer and Senior Executive Vice President Robert D. Lister. The third amendment extends his agreement’s term to December 31, 2029, with compensation and severance terms unchanged from prior disclosures.
The amendment clarifies equity treatment. If IMAX terminates Mr. Lister for cause or he resigns without Good Reason before December 31, 2029, all granted but unvested equity awards are cancelled without consideration. However, if he resigns after giving at least six months’ written notice, or if his employment ends after December 31, 2029 because IMAX does not offer to continue his employment on substantially similar terms, all unvested equity awards as of that date will, under the LTIP’s Service Factor provision, continue to vest on the original schedule, with PSUs remaining subject to their original performance conditions.
IMAX Corporation reported strong results for the quarter ended June 30, 2026, with revenue of $102.8 million, up 12% year-over-year and gross margin of 61.2%. Net income was $15.9 million, up 30%, for a 15.5% net margin, and diluted EPS rose to $0.27, up 35% year-over-year. Adjusted net income was $24.2 million and record second-quarter adjusted diluted EPS reached $0.43, up 65%.
Total Adjusted EBITDA was $48.0 million with a margin of 46.6%. Content Solutions revenue grew modestly to $34.7 million, supported by global box office of $285 million, IMAX’s highest second-quarter box office since 2019. Technology Products and Services revenue increased to $64.8 million, driven by higher system sales, rentals, and renewals.
Year-to-date, net cash provided by operating activities rose 19% to $36.0 million. IMAX reported available liquidity of $551 million, including $159.9 million of cash and cash equivalents and significant revolving credit capacity, against total debt of $292 million. The company repurchased 404,866 shares for $13.7 million in the quarter and ended with a system network of 1,876 IMAX systems and a backlog of 421 systems.
IMAX Corporation reported the results of its 2026 Annual General Meeting of Shareholders held on June 10, 2026. Shareholders elected ten directors, including Gail Berman, Richard L. Gelfond, and Jennifer Wong, to serve until the next annual meeting in 2027 or until their successors are chosen.
Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent auditors until the 2027 annual meeting and authorized the board to set their remuneration. In an advisory vote, shareholders approved the compensation of the company’s Named Executive Officers, indicating support for the current executive pay structure.
IMAX Corporation reported mixed first-quarter 2026 results. Revenue declined 6% year-over-year to $81.4 million, with gross margin down to $45.8 million and Total Adjusted EBITDA falling 18% to $30.5 million. GAAP net income decreased 26% to $6.1 million, but net income attributable to common shareholders rose 83% to $4.2 million.
On a per-share basis, diluted EPS increased to $0.07 from $0.04, while adjusted diluted EPS grew 31% to $0.17. Global box office reached $260 million, down 13% due mainly to a tougher comparison in China, although box office outside Greater China grew 67%. IMAX reaffirmed full-year 2026 guidance for $1.4 billion in global box office and highlighted continued network expansion to 1,865 systems, system backlog of 435, and available liquidity of $528 million.
IMAX Corporation temporarily adjusted its leadership structure while CEO Richard Gelfond is on medical leave. The board appointed Robert D. Lister, currently Chief Legal Officer and Senior Executive Vice President, to serve as interim principal executive officer until May 1, 2026, when Mr. Gelfond will resume the role.
Mr. Lister will keep his existing responsibilities and will not receive any additional compensation for this interim assignment. The company states there are no special arrangements, related-party transactions, new or amended contracts, or family relationships connected to his appointment, and incorporates his biography by reference from a prior proxy statement.
IMAX Corporation announced that CEO Richard Gelfond is on a temporary medical leave of absence while he receives treatment for pneumonia and recovers. During his absence, the company’s senior executives are handling day-to-day operations in coordination with Board Chair Darren Throop and with regular communication with the full Board.
The leadership team highlighted in the announcement includes CFO Natasha Fernandes, Chief Marketing Officer Anne Globe, Chief Legal Officer Rob Lister, and IMAX Theatres President Mark Welton, all of whom have significant tenure with the company. IMAX stated it is providing this update to avoid speculation about Gelfond’s absence from upcoming events and will offer further updates as appropriate.
IMAX Corporation reported record results for 2025, with total revenue of $410.2 million, up 16%, and net income attributable to common shareholders of $34.9 million, up 34%. Adjusted net income rose to $80.6 million and diluted adjusted EPS climbed to $1.45, an increase of 53%.
Full-year gross margin expanded to $246.2 million, or 60% of revenue, while total Adjusted EBITDA increased 33% to a record $184.9 million with a 45.1% margin. Global IMAX box office reached a best-ever $1.28 billion, and the company grew its commercial network to 1,796 multiplex systems with a backlog of 434.
Operating cash flow jumped 79% to a record $127.1 million, and free cash flow rose to $85.2 million. IMAX ended 2025 with $545 million in available liquidity and total debt of $289 million, and issued $250 million of 0.750% Convertible Senior Notes due 2030. Management’s 2026 guidance targets $1.4 billion in IMAX box office, 160 to 175 system installations, and adjusted EBITDA margin in the mid‑40% range.
IMAX Corporation completed a private Rule 144A sale of $250 million aggregate principal amount of 0.750% Convertible Senior Notes due 2030, including the full exercise of a $30 million option. The notes pay interest semi‑annually beginning May 15, 2026 and mature on November 15, 2030, unless earlier converted, redeemed, or repurchased.
Net proceeds are expected to be $241.1 million. IMAX plans to use the cash, along with cash on hand and borrowings under its credit facility, to fund capped call transactions and repurchase its 0.500% Convertible Senior Notes due 2026. The company agreed to repurchase $229.7 million principal of the 2026 notes for a total cash price of $276.0 million, including accrued interest.
The initial conversion rate is 23.5743 shares per $1,000 (conversion price ≈ $42.42) with customary adjustments; upon conversion, IMAX will settle in cash or cash plus shares. The capped call’s initial cap price is $57.1025 (a 75% premium to the November 3, 2025 close) and cost approximately $21.9 million. The notes are redeemable at IMAX’s option on or after November 20, 2028 if the share price exceeds 130% of the conversion price for the specified trading periods. An initial maximum of 7,661,650 shares may be issuable upon conversion based on the initial maximum conversion rate.
IMAX Corporation furnished a press release announcing its financial and operating results for the quarter ended September 30, 2025, under Item 2.02 of a Form 8-K.
The release is attached as Exhibit 99.1. The information is furnished, not filed, which means it is not subject to Section 18 of the Exchange Act and will be incorporated by reference only if specifically stated.